Matthew Baggott - New Entactogens: Motivations and Progress

Name: Matthew Baggott - New Entactogens: Motivations and Progress
Start: 2024-11-26T18:30:00+01:00
End: 2024-11-26T21:00:00+01:00
Location: Södra hamnvägen 9, SE-115 41 Stockholm, Sverige

Schedule

Tue Nov 26 2024 at 06:30 pm to 09:00 pm

UTC+01:00

Location

Södra hamnvägen 9, SE-115 41 Stockholm, Sverige | Stockholm, ST

We welcome you to this social evening at Blivande exclusively for members of NPV or Blivande! Doors open at 18:30, a webinar with Matthew Baggott will take place between 19:00-20:00, followed by time to hang out in the beautiful space of Blivande. Snacks and drinks will be provided.
-->> To become a member, get access to member-only events and support the work of NPV, follow this link: https://www.psykedeliskvetenskap.org/medlem <<--
About the webinar:
This talk will brief upon the leading edge development of entactogenic molecules - both their basic research and clinical applications - by Dr. Matthew Baggott of Tactogen, having some of the most extensive expertise in and documented contributions towards this particular area. It will also comment on the U.S. FDA rejection of Lykos' (formerly MAPS) MDMA-assisted therapy for PTSD treatment proposal, and implications for the psychedelic medicalization efforts and their own work with entactogens.
Matt will explain how their company optimizes certain non-ideal properties of MDMA and discuss the results of their pharmacological assays focusing on several most promising entactogenic molecules. He will also exemplify practically useful results of clinical studies relevant to use in therapy as well as for wellbeing.
About Matthew Baggott:
Matt is a PhD neuroscientist and data scientist, having spent over 30 years researching psychedelics, including preclinical pharmacology, clinical research, neuroscience, genomics, and drug development, and has authored tens of scientific papers on preclinical and clinical effects of entactogens and several patents on optimized substances for mental disorders or enhancement.
He is the co-founder & CEO at the public benefit company Tactogen (https://tactogen.com/) based in San Francisco Bay Area, developing mental wellness medicines with focus on entactogenic substances with improved properties and the goal to make transformative medicines safer, more effective, and more accessible - "for everyone".
He has criticized the historically predominant government-funded MDMA research, and exemplifies the opposite approach - addressing the real phenomena in humans limiting the safety, efficacy and availability of entactogens - which, he believes, has the potential to help millions of people.